These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 22977305)

  • 1. Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.
    Miyares MA; Davis K
    Vasc Health Risk Manag; 2012; 8():483-93. PubMed ID: 22977305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
    Shinkai H
    Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?
    Page MM; Hooper AJ; Burnett JR
    Expert Opin Pharmacother; 2016; 17(2):275-81. PubMed ID: 26642232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
    Kones R
    Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
    Johns DG; Duffy J; Fisher T; Hubbard BK; Forrest MJ
    Drugs; 2012 Mar; 72(4):491-507. PubMed ID: 22356288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.
    Chapman MJ; Le Goff W; Guerin M; Kontush A
    Eur Heart J; 2010 Jan; 31(2):149-64. PubMed ID: 19825813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.
    Brinton EA; Kher U; Shah S; Cannon CP; Davidson M; Gotto AM; Ashraf TB; McCrary Sisk C; Dansky H; Mitchel Y; Barter P;
    J Clin Lipidol; 2015; 9(1):65-71. PubMed ID: 25670362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
    Mohammadpour AH; Akhlaghi F
    Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
    Krauss RM; Pinto CA; Liu Y; Johnson-Levonas AO; Dansky HM
    J Clin Lipidol; 2015; 9(1):93-102. PubMed ID: 25670366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.
    van der Tuin SJ; Kühnast S; Berbée JF; Verschuren L; Pieterman EJ; Havekes LM; van der Hoorn JW; Rensen PC; Jukema JW; Princen HM; Willems van Dijk K; Wang Y
    J Lipid Res; 2015 Nov; 56(11):2085-93. PubMed ID: 26342106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D; Carlson GL; Sapre A; Tribble D; McKenney JM; Littlejohn TW; Sisk CM; Mitchel Y; Pasternak RC
    Am Heart J; 2009 Feb; 157(2):352-360.e2. PubMed ID: 19185645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis.
    Li C; Zhang W; Zhou F; Chen C; Zhou L; Li Y; Liu L; Pei F; Luo H; Hu Z; Cai J; Zeng C
    PLoS One; 2013; 8(10):e77049. PubMed ID: 24204732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anacetrapib, a cholesteryl ester transfer protein inhibitor.
    Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2012 Jan; 21(1):103-9. PubMed ID: 22191425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anacetrapib: a potential new therapy for dyslipidemia.
    Robinson LB; Frishman WH
    Cardiol Rev; 2014; 22(5):253-61. PubMed ID: 24618931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
    Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
    Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.
    Yvan-Charvet L; Kling J; Pagler T; Li H; Hubbard B; Fisher T; Sparrow CP; Taggart AK; Tall AR
    Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1430-8. PubMed ID: 20448206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
    Barter P; Rye KA
    Trends Pharmacol Sci; 2011 Dec; 32(12):694-9. PubMed ID: 22088767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.
    Reyes-Soffer G; Millar JS; Ngai C; Jumes P; Coromilas E; Asztalos B; Johnson-Levonas AO; Wagner JA; Donovan DS; Karmally W; Ramakrishnan R; Holleran S; Thomas T; Dunbar RL; deGoma EM; Rafeek H; Baer AL; Liu Y; Lassman ME; Gutstein DE; Rader DJ; Ginsberg HN
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):994-1002. PubMed ID: 26966279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of dyslipidemia - is here still place for CETP-inhibitors?].
    Murín J; Pernický M; Kiňová S
    Vnitr Lek; 2016; 62(10):789-794. PubMed ID: 27900865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.